Appili Has Disappointing Trial Results

Shares of Appili Therapeutics shed more than half their value on Friday after the Halifax drug discovery company released disappointing trial results for a drug candidate intended to treat COVID-19.
The company released a statement before the market opened on Friday saying the Phase 3 clinical trial evaluating Favipiravir as a treatment for mild-to-moderate COVID-19 “did not achieve statistical